MedElevator
Войти в исследования Clinical laboratory · 2026
Clinical and Laboratory Characteristics of ABO-Incompatible Hemolytic Disease of the Fetus and Newborn.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Han Joo, Jung Kiwook, Kim Jin Seok, Seo Suk Won, Chung Yousun, Hwang Sang-Hyun, Oh Heung-Bum, Kim Hyungsuk, Ko Dae-Hyun
Аннотация
BACKGROUND: ABO incompatibility is the most common cause of hemolytic disease of the fetus and newborn (HDFN). We investigated HDFN at our institute and discuss clinical characteristics and considerations during transfusions and laboratory testing.
METHODS: We reviewed the medical records of newborns with HDFN due to ABO incompatibility over a period of 5 years. Laboratory results such as the ABO blood type of mothers and newborns, direct antiglobulin test, hemoglobin, and total bilirubin were collected. History of transfusion and phototherapy were also taken.
RESULTS: During the 5 years, 275 newborns were diagnosed with HDFN by ABO blood type testing and crossmatching. Group O mothers were predominant, with 259 newborns, followed by B and A types, with 11 and five newborns, respectively. For the newborns, group A was the most common, with 151, followed by group B with 108 and AB with 16 newborns. The most common type of incompatibility was O/A, accounting for 54.9%, followed by O/B, B/AB, and A/AB at 54.9%, 4.0%, and 1.8%, respectively. DAT was conducted on only half of the group O mothers, and among them, 38.5% had positive results. For the 16 newborns of non-O mothers, six underwent DAT, and all were negative. Further, 21.6% and 31.3% of newborns from group O and non-group O mothers received transfusions, and 49.4% and 43.8% received phototherapy, respectively.
CONCLUSIONS: Our findings highlight the importance of considering ABO HDFN even in DAT-negative neonates. Reverse typing may provide important diagnostic value, especially in transfusion settings with ABO compatibility with the maternal blood group.
METHODS: We reviewed the medical records of newborns with HDFN due to ABO incompatibility over a period of 5 years. Laboratory results such as the ABO blood type of mothers and newborns, direct antiglobulin test, hemoglobin, and total bilirubin were collected. History of transfusion and phototherapy were also taken.
RESULTS: During the 5 years, 275 newborns were diagnosed with HDFN by ABO blood type testing and crossmatching. Group O mothers were predominant, with 259 newborns, followed by B and A types, with 11 and five newborns, respectively. For the newborns, group A was the most common, with 151, followed by group B with 108 and AB with 16 newborns. The most common type of incompatibility was O/A, accounting for 54.9%, followed by O/B, B/AB, and A/AB at 54.9%, 4.0%, and 1.8%, respectively. DAT was conducted on only half of the group O mothers, and among them, 38.5% had positive results. For the 16 newborns of non-O mothers, six underwent DAT, and all were negative. Further, 21.6% and 31.3% of newborns from group O and non-group O mothers received transfusions, and 49.4% and 43.8% received phototherapy, respectively.
CONCLUSIONS: Our findings highlight the importance of considering ABO HDFN even in DAT-negative neonates. Reverse typing may provide important diagnostic value, especially in transfusion settings with ABO compatibility with the maternal blood group.